1. |
Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease[J]. Lancet, 1990, 335(8697): 1078-1080.
|
2. |
Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s disease[J]. Semin Arthritis Rheum, 1998, 27(4): 197-217.
|
3. |
Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study[J]. Arch Dermatol, 1999, 135(5): 529-532.
|
4. |
D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Acad Sci USA, 1994, 91(9): 4082-4085.
|
5. |
Stambe C, Wicks IP. TNFalpha and response of treatment-resistant adult-onset Still’s disease to thalidomide[J]. Lancet, 1998, 352(9127): 544-545.
|
6. |
Keenan RJ, Eiras G, Burckart GJ, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506[J]. Transplantation, 1991, 52(5): 908-910.
|
7. |
Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells[J]. Life Sci, 1994, 55(2): 77-92.
|
8. |
Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity[J]. Science, 2010, 327(5971):1345-1350.
|
9. |
杜趁香,王焱. 沙利度胺抗肿瘤作用的研究进展[J]. 河南科技大学学报(医学版), 2009,1(27): 79-80.
|
10. |
Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet’s syndrome. A randomized, double-blind, placebo-controlled trial[J]. Ann Intern Med, 1998, 128(6): 443-450.
|
11. |
Ehrlich GE. Behçet’s disease and the emergence of thalidomide[J]. Ann Intern Med, 1998, 128(6): 494-495.
|
12. |
Wulff CH, Hoyer H, Asboe-Hansen G, et al. Development of polyneuropathy during thalidomide therapy[J]. Br J Dermatol, 1985,112(4): 475-480.
|